問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Link to Hospital

  • 2,634

    Total Beds

  • 1,095

    Total Doctors

  • jmventcc@cgmh.org.tw
  • CHANG-CHIEN, CHIA-MIN
  • 07-7317123#6416
  • 833Kaohsiung CityKaohsiung NiaosongNo. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833 , Taiwan (R.O.C.)

Recruiting Trial

554Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1389Cases

2011-07-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-11-01 - 2017-10-31

Phase III

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Condition/Disease

    Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

  • Test Drug

    ASP8273

Participate Sites
9Sites

Terminated9Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2008-06-01 - 2009-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-04-01 - 2010-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2007-06-30 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-07-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-09-30 - 2014-12-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-11-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 131 132 133 134 135 139
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB